Through the Centre for Drug Candidate Optimisation (CDCO), Cancer Therapeutics is highly proficient in physical and preformulation chemistry, pharmacokinetics, drug metabolism and bioanalysis.

Profiling of compounds routinely includes analysis of physicochemical properties, permeability, metabolism and metabolite profiling, metabolic drug-drug interactions, in vivo pharmacokinetics, stability testing and impurity profiling. CDCO also provides expertise in preclinical formulation development, solid-state characterisation and salt selection for lead compounds.

Since 2003 CDCO has worked on more than 50 collaborative drug discovery programs, and contributed to more than 15 novel candidates moving into clinical development.